I did twitter the Ord Minett report on Stocktwits.
This may help those USA investors make up their mind
Key stat PRR vs Dendron at early stage 21% V 19% Disease modification.
Table 6: Oncology Treatments, Early Stage Results
Treatment Status
DNDN Provenge Approved
PRR CVac Phase III
Source: Company Presentation
Activity
DNDN Therapeutic vaccine for prostate cancer
PRR Therapeutic vaccine for ovarian cancer
Disease Modification
Dendron19%
Prima 21%
Its all good & they know CVac works!
nasdaq/frankfurt, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |